| DCB (N=11) |
NDB (N=10) |
P-value | |
|---|---|---|---|
| Smoking history | |||
| No | 4 (36.4%) | 1 (10.0%) | 0.366 |
| Yes | 7 (63.6%) | 9 (90.0%) | |
| Drug type | |||
| Atezolizumab | 2 (18.2%) | 0 (0%) | 0.262 |
| Camrelizumab | 0 (0%) | 1 (10.0%) | |
| Durvalumab | 0 (0%) | 2 (20.0%) | |
| Nivolumab | 3 (27.3%) | 2 (20.0%) | |
| Pembrolizumab | 6 (54.5%) | 5 (50.0%) |